Skip to content
PeptideAI
Human trialsskinhealinghair

GHK-Cu (topical)

The best-evidenced cosmetic peptide there is: a copper-carrying tripeptide that pushes fibroblasts to rebuild collagen, elastin and glycosaminoglycans while dialling down matrix breakdown.

Also known as Copper tripeptide-1, Copper peptide, Gly-His-Lys-Cu, GHK copper, Blue copper peptide, Neova, Skin Biology CP Serum

Human trials — Studied in people, typically early phase or small — promising rather than proven.

GHK-Cu has genuine published human facial and wound-healing data plus a deep mechanistic literature, which puts it well ahead of the rest of this class. Most of the controlled cosmetic trials are still small, industry-funded and short.

How it works

GHK is a naturally occurring fragment of collagen alpha-2(I) that binds copper(II) with almost ideal affinity for physiological exchange, so it acts as a shuttle rather than a chelator. Once delivered, the complex upregulates collagen I and III, elastin, decorin, versican and glycosaminoglycan synthesis in fibroblasts, and rebalances MMP-1/MMP-2 against their TIMP inhibitors so the skin builds more matrix than it degrades. Gene-expression work shows GHK-Cu shifts several thousand human genes, including antioxidant and DNA-repair sets, which is where the broader anti-ageing claims come from. Plasma GHK falls roughly by half between age 20 and age 60, which is the usual rationale offered for replacing it topically.

Targets: Copper(II) transport, Collagen I and III synthesis, Elastin and decorin, MMP-1 / MMP-2 vs TIMP-1 / TIMP-2 balance, Antioxidant and DNA-repair gene programmes

Dosing

ProtocolDoseFrequencyRoute
Standard leave-on serumApply to clean damp skin and let it absorb before other actives; most people put it in the evening slot.—once or twice dailytopical
Microneedling or mesotherapy adjunctApplied to the skin surface right after a 0.5-1.0 mm roller or pen pass, when channels are still open.—immediately after needling, then daily for 3-5 daysintradermal
  • · Effective cosmetic concentrations run 0.1% to 1% w/w. Below 0.05% you are mostly buying the blue colour; above 2% irritation climbs without added benefit. 200 mg of powder into 20 mL of water or a light serum base gives 1%.
  • · Use a sterile, preservative-free 0.05-0.1% solution for this. Do not push cosmetic-grade serums containing fragrance or preservatives through open channels.

Titration

Start at 0.1% and step up over 2-3 weeks if there is no stinging or flaking. Sensitive and rosacea-prone skin often tops out around 0.2%.

Cycling

No cycling needed for topical use; it is used continuously. Injected or needled copper protocols should be limited to short courses because copper loading is cumulative.

Work out your exact syringe units →

Pharmacology

Half-life
Not meaningfully defined for topical use; the complex dissociates and the copper is handed off locally within hours of application.
Onset
Hydration and barrier feel improve in 2-4 weeks; firmness and fine-line changes need 8-12 weeks of daily use.
Routes
topical, intradermal, subcutaneous
Molecule
Copper(II)-bound tripeptide
Sequence length
3 amino acids
Molecular weight
403.9 Da

Handling

Diluent
Distilled or deionised water, or a finished fragrance-free serum base
Typical mix
10 or 20 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Sealed and dry at room temperature for months; freezer for long-term storage.
Reconstituted
Refrigerated in an opaque or amber bottle; use an aqueous solution within about 30 days unless properly preserved.
Light sensitive
Yes — keep it out of the light

Mixing

Dissolves readily and turns a deep blue — that colour is the copper complex and is normal. Bacteriostatic water is only relevant if you are preparing an injectable solution.

Side effects

  • commonStinging or transient redness on application— Usually concentration-dependent and settles within a week or two.
  • commonBlue-green staining of skin, pillowcases and towels— Cosmetic only; washes out of most fabrics.
  • uncommonContact dermatitis— More likely in people with a known nickel or copper jewellery sensitivity.

Do not use if

  • Wilson's disease or any disorder of copper handling — repeated copper loading is a real problem, not a theoretical one.
  • Known copper contact allergy.

Combining it

  • redundanttripeptide-1 — Same peptide backbone without the copper; running both adds nothing.
  • synergymatrixyl — Different signalling routes to the same fibroblast output; commonly layered.
  • conflictl-ascorbic-acid — Direct vitamin C reduces copper(II) and destroys the complex — separate them by application or by time of day.
  • cautiontretinoin — Combined irritation potential; alternate nights rather than layering at first.

What to monitor

  • · No bloodwork needed for topical use.
  • · Photograph the same area under the same lighting monthly — the changes are slow enough that memory is unreliable.

Legal status

Permitted worldwide as a cosmetic ingredient under the INCI name Copper Tripeptide-1. Injectable GHK-Cu is not an approved drug anywhere and is sold only as a research chemical.

References

  • Pickart & Margolina 2018, regenerative and protective actions of GHK-Cu (Int J Mol Sci) (review)
  • Pickart 2008, GHK peptide as a natural modulator of tissue repair (review)

Mechanism in depth

The Core entry tells you GHK-Cu turns on collagen genes. What it does not tell you is why the gene list is so absurdly long, and that is the interesting part. GHK is not a receptor ligand in the ordinary sense — no GHK receptor has ever been cloned. It works through copper. Copper(II) is a cofactor for lysyl oxidase, which cross-links collagen and elastin, for superoxide dismutase 1, for cytochrome c oxidase, and for the copper-sensing transcription machinery that runs through the MTF-1 and ATOX1 axes. ATOX1 in particular is a copper chaperone that doubles as a transcription factor, and putting bioavailable copper into a fibroblast shifts a whole redox-sensitive transcriptional programme rather than a single pathway. That is why Broad Institute Connectivity Map analysis of GHK, which is where the frequently quoted 'over 4,000 genes shifted' figure originates, reads more like a global reprogramming signature than a growth factor response. It also means the effect size at any single endpoint is modest and the claims are broad, which is exactly the pattern you see in the clinical literature. Downstream of that, the practically relevant outputs are: collagen I and III transcription up, decorin and versican up, glycosaminoglycan and dermatan sulfate synthesis up, MMP-1 and MMP-2 down while TIMP-1 and TIMP-2 go up, and antioxidant enzymes induced. The MMP/TIMP shift matters more than the synthesis numbers for photoaged skin, because photoaged dermis is a degradation problem before it is a production problem. GHK also has genuine chemotactic and anti-inflammatory activity — it recruits macrophages and mast cells to wounds and suppresses TGF-beta-driven fibrotic overshoot at the same time, which is the unusual combination behind the low-scar healing claims.

What usually goes wrong

Four failure modes account for most disappointment. First, buying blue water: products advertising 'copper peptides' at 0.05% or below are decorative, and the deep blue colour is not proof of concentration because a tiny amount of the complex colours a whole bottle. Second, destroying it in the routine — layering it under a vitamin C serum, or mixing it into an acidic base, turns an expensive peptide into copper ions and peptide fragments. Third, pushing concentration to fix a delivery problem. If 1% is not working, 3% will not work either; it will just make your face sting and stain your pillowcase. Fourth, and this is the one people underrate, mesotherapy and injected copper protocols. Copper is cumulative, hepatically eliminated and genuinely toxic in overload, and cosmetic-grade GHK-Cu powder is not sterile, not endotoxin-tested and frequently not even assayed. People have given themselves granulomatous reactions injecting cosmetic-grade copper peptide. If you are needling it, use a sterile preservative-free preparation at 0.05-0.1% and keep courses short. Also worth knowing: the blue-green staining is not just cosmetic annoyance — on grey or blonde hair from a scalp serum it is genuinely visible and takes several washes to clear.

Titration ladder

  1. —0-2 — 0.1% w/w once daily at night. Watch for stinging on the nasolabial folds and around the eyes, which is where it shows up first.
  2. —2-4 — 0.5% w/w once daily, or 0.1% twice daily. If you are rosacea-prone this is usually where you stop.
  3. —4+ — 1% w/w daily. This is the top of the useful range. Above 2% irritation climbs steeply and there is no evidence the extra does anything.

Bloodwork worth running

MarkerWhenWhy it matters
Serum copper and ceruloplasminBaseline and at 3 months if you are running injected or needled copper protocols, or at any point if you have unexplained fatigue, neurological symptoms or liver enzyme elevation.Only relevant if you are injecting or mesotherapy-dosing copper peptide repeatedly, or applying gram quantities of a high-percentage product daily over a large surface. Topical facial use at 0.1-1% does not move systemic copper and does not need testing.Act if: Serum copper above the lab reference range, or ceruloplasmin above range with rising ALT, means stop the copper entirely and get a proper workup.
ALT / ASTBaseline and 3 months on injected or needled protocols only.Copper overload is hepatotoxic before it is anything else. This is only a real concern for repeated injected or intradermal copper, not for a face serum.Act if: Any new ALT elevation above 1.5x the upper limit of normal with no other explanation — stop and investigate.

Pharmacokinetics

Metabolism
Two separate fates. The peptide backbone is degraded by skin and plasma peptidases to Gly, His and Lys. The copper is exchanged into the normal copper-handling pool; GHK binds copper(II) with an affinity deliberately close to that of albumin and histidine, which is why it functions as a shuttle rather than a chelator and why it can hand copper off to a target rather than sequestering it.
Elimination
Copper is eliminated hepatically in bile, which is the entire reason Wilson's disease is a real contraindication rather than a decorative one. Peptide fragments enter normal amino acid pools.

Receptor targets

  • Copper(II) — as a transport ligand, not a receptor — Log K around 16 for the GHK-Cu(II) complex at physiological pH, deliberately in the same range as albumin and free histidine so copper can be exchanged rather than locked up

    Delivers exchangeable copper into cells and to copper-dependent enzymes: lysyl oxidase, SOD1, cytochrome c oxidase, tyrosinase.

  • Lysyl oxidase (copper-dependent) — Not a direct binding interaction — cofactor supply

    Cross-links newly made collagen and elastin, which is what converts raw collagen synthesis into actual tensile strength.

  • MMP-1 / MMP-2 versus TIMP-1 / TIMP-2 — Transcriptional, not binding

    Tilts the balance toward matrix preservation; this is probably the dominant mechanism in visibly photoaged skin.

  • Decorin and versican — Transcriptional

    Small leucine-rich proteoglycans that control collagen fibril diameter and spacing. Rebuilding these is the difference between disorganised scar collagen and normal dermal architecture.

  • ATOX1 / MTF-1 copper-responsive transcription — Indirect, via copper loading

    The most plausible explanation for the very broad gene-expression signature attributed to GHK.

Trials

  • Randomised controlled trial of topical copper tripeptide complex after CO2 laser resurfacing (Miller et al., Archives of Facial Plastic Surgery) Investigator-initiated RCT · 2006

    No significant difference from control in objective erythema resolution or wrinkle improvement. Patient-reported satisfaction with overall skin quality was significantly higher in the copper peptide arm (p = 0.04). This is the honest shape of the GHK-Cu clinical evidence: subjects like it, instruments struggle to see it.

  • Scalp regimen combining a hydroxy acid scrub with a copper tripeptide serum (Patel et al., Cureus) Open-label safety, efficacy and tolerability assessment · 2024

    Safety, efficacy and tolerability of the combined scalp regimen. Open-label and multi-component, so it cannot isolate the copper peptide's contribution.

What to expect, and when

Week 1-2: barrier feel and hydration improve, which is real but is the least peptide-specific part of the effect. Week 4: skin tone and surface texture start to look different in photographs, not in the mirror. Week 8-12: this is where fine lines and firmness change if they are going to. Week 16-24: the MMP/TIMP shift compounds and this is the point at which photoaged skin looks meaningfully different. If you are using it for wound or post-procedure healing rather than ageing, the timescale is completely different — days, not months, and the effect is much more obvious.

Stacking and comparisons

The vitamin C conflict is the one that actually costs people results, and it is chemistry, not caution. L-ascorbic acid reduces copper(II) to copper(I), which collapses the complex and, worse, sets up Fenton-type redox cycling that generates hydroxyl radicals in your skin. Put GHK-Cu at night and vitamin C in the morning, or use copper-free Tripeptide-1 if you insist on layering. The same logic applies to any strong reducing agent: ferulic acid, sodium ascorbyl phosphate to a lesser degree, and high-dose niacinamide is fine but glutathione is not. Direct acids below about pH 4 will also strip copper off the peptide, so do not layer it straight onto a glycolic or salicylic product — wait or alternate. The pairing that genuinely works is GHK-Cu with a matrikine like pal-KTTKS or Matrixyl 3000, because they drive fibroblast output through independent routes with no shared chemistry to fight over. GHK-Cu plus a retinoid is well tolerated by most people but is two irritants in one routine, so alternate nights for the first month. Post-procedure, GHK-Cu plus thymosin beta-4 immediately after microneedling is the standard repair stack and is the one context where topical delivery of both is actually plausible, because the barrier is open.

Against the rest of this class, GHK-Cu has the deepest mechanistic literature and the most independent human data, and it is still not close to a retinoid. Tretinoin at 0.025-0.1% has decades of randomised photoageing trials with effect sizes GHK-Cu has never approached. The honest positioning is adjunct, not replacement. Against Matrixyl, GHK-Cu is the better-evidenced mechanism but Matrixyl has the better trial — Robinson 2005 is a proper 93-subject randomised vehicle-controlled facial study and GHK-Cu has nothing equivalent. Against copper-free Tripeptide-1, GHK-Cu is what almost all the research actually used, so choose the copper form unless a formulation conflict forces your hand. Against AHK-Cu, GHK-Cu is better studied for skin and AHK-Cu has the only dermal-papilla hair data, so they are not interchangeable by target.

Rough cost

$12–$90/month. Raw GHK-Cu powder runs roughly $20-60 per gram from cosmetic ingredient suppliers, and one gram at 1% makes 100 mL of serum, which is several months of face use — so DIY is genuinely cheap at around $10-15 a month. Finished branded serums run $30-90 a month. These are market observations from ingredient and retail listings, not a sourced pricing study.

Genuinely uncertain

  • No quantified topical bioavailability exists. Every percentage figure circulating for GHK-Cu skin penetration traces back to supplier material rather than a published permeation study.
  • Whether the intact copper complex reaches the dermis, or whether it dissociates in the stratum corneum and delivers copper plus free peptide separately, is genuinely unresolved and would change how you think about formulating it.
  • The 'over 4,000 genes' figure comes from Connectivity Map analysis of GHK in cultured cell lines at concentrations that may not be achievable in skin. It is a real analysis, not an invented one, but it is not a skin measurement.
  • The claim that plasma GHK falls from around 200 ng/mL at age 20 to around 80 ng/mL at age 60 is repeated everywhere and is attributed to Pickart's own work. I could not resolve an independent primary source for those specific numbers in this session.
  • The molecular weight of 403.9 Da in the Core record depends on which salt and hydration state is being quoted; free GHK is 340.4 Da and the anhydrous 1:1 copper complex is around 403-404 Da. Vendor certificates vary.
  • No human trial of injected or intradermal GHK-Cu exists at all. The microneedling protocols in the Core record are extrapolation from topical use plus community practice.
  • The safe cumulative topical copper dose has never been established. The Wilson's disease contraindication is sound reasoning, not a documented case series.

Papers